INTRODUCTION
Insulin-like growth factors (IGFs) were originally described as endocrine mediators of the action of GH on cartilage (1) but subsequent work has shown that they are involved in the regulation of numerous cellular procOEm-9609/94/0904-0909$03.00/0 Molecular Endocrinology Copyright Q 1994 by The Endocrine Society esses, binding to receptors in many tissues with important autocrine, paracrine, and endocrine actions (2, 3). In contrast to other growth factors, IGF-I and IGF-II are normally present in plasma at high concentrations (150-700 rig/ml) (3) in association with specific binding proteins, suggesting that they have an endocrine role. The IGFs persist in plasma long after linear growth has ceased.
One potential function for the IGFs in adults is regulation of lipid metabolism.
Recently we reported that plasma IGF-I was inversely correlated with apolipoprotein B, the protein component of the low density lipoprotein (LDL) particle, and with LDL cholesterol levels in man (4). To determine whether this relation was due in part to an increase in LDL receptor expression, we studied the effects of IGF-I on LDL metabolism in cultured human skin fibroblasts.
While the fibroblast culture system is a good model system for peripheral tissue lipoprotein receptors, the use of IGF-I is complicated by the finding that fibroblasts, like many other cultured cells, actively secrete binding proteins that inhibit IGF-I action (5, 6). To eliminate this difficulty we have used two analogs of IGF-I [Gln3,Ala4,Tyr'5,Leu'6]-IGF-I(QAYL)and[Phe-',Val',Asn2,Gln3,His4,Sers,Hisg, Glu'2,Tyr'5,Leu'6]IGF-l [B-chain mutant (BCM)], which bind normally to the IGF-I receptor but which have very poor affinity for the interfering binding proteins (7). The results show that IGF-I and its receptor-binding analogs increase LDL receptor expression and do so by a mechanism that is independent of the measured levels of LDL receptor mRNA and also of the suppressive effect of exogenous lipoproteins. Half-maximum stimulation of ['251]LDL binding was seen at 0.6 rig/ml QAYL and 0.5 rig/ml BCM, with maximum effects obeserved at 5 rig/ml. This suggests that IGF-I increases LDL receptor expression with attenuation of the response by binding proteins of cellular origin. Figure 1 B gives the time course of LDL receptor increase in response to QAYL. A significant difference between control and QAYL-treated wells first appeared at 4 h (32% increase, P = 0.03) and continued for at least 48 h. Figure 2 shows that in intact fibroblasts treated with 5 rig/ml QAYL the principal effect on LDL receptor activity was a 72% increase in LDL-binding capacity (from 7.7 + 0.7 ng LDL/mg protein to 13.2 f 0.7 ng/ mg, P < 0.0001). A smaller increase in affinity for LDL was also found as reflected in a 38% reduction in the dissociation constant (KJ for LDL (from 13.1 f 2.2 pg/ ml to 8.1 + 0.9 pg/ml, P = 0.039). The increase in LDL receptor mass was confirmed by immunoblot analysis of triplicate whole cell extracts (data not shown) in which polyclonal anti-LDL receptor antibodies detected 56 f 10% more receptors per milligram of protein in QAYL-treated cells (P = 0.008). The effect of IGF-I and QAYL was apparent under physiological conditions in which LDL was present in the culture medium and LDL receptors were downregulated. Figure 3 shows that in the presence of LDL, QAYL resulted in a 65 + 17% (SE) by LDL All cells were grown for 4 days in 10% fetal bovine serum and then for 24 h in 50 pg/ml LDL + 250 rig/ml IGF-I or 50 @g/ml LDL f 5 rig/ml QAYL as indicated.
RESULTS

IGF-I increased
Either 0.1% BSA (experiment depicted by the right two bars) or 7 mg/ml LPDS (separate experiment, left two bars) was included during the final incubation.
The cells were washed twice and incubated with serum-free medium at 37 C for 30 min before placing on ice for measurement of receptor-specific [?]LDL binding. Results are the mean of six wells with SE shown.
The effects of QAYL (P = 0.02) and IGF-I (P = 0.01) were both statistically significant.
or not lipoprotein-deficient human plasma-derived serum (LPDS) was present in the medium in addition to LDL. The preparation of LPDS used contributed 3.5 ng IGF-l/ml culture medium when used at 7 mg/ml protein.
In contrast, when LDL receptors were induced by growth in LPDS without LDL, IGF-I did not alter [""I]-LDL binding. In four experiments, each conducted in triplicate, ['251 ]LDL binding was 32.4 + 1.9 ng/mg in control wells and 31.6 + 3.5 ng/mg in wells treated with 250 rig/ml IGF-I for 24 h (P = 0.84).
The effects of IGF-I were blocked by the monoclonal anti-IGF-I receptor antibody a-IR3 (Fig. 4) . In the absence of antibody, QAYL increased specific LDL binding by 116% (P = O.OOl), similar to the 104% increase observed in the presence of nonspecific immunoglobulin G (P = 0.0008). However, when (u-IR3 was present, no significant difference was seen after QAYL addition.
Increased expression of LDL receptors after IGF-I treatment occurred without an increase in LDL receptor mRNA (Fig. 5A) . Levels of LDL receptor mRNA measured by a precise (10.4% coefficient of variation) RNA excess solution hybridization assay were unchanged in samples treated for up to 24 h with 5 rig/ml QAYL. The statistical power for detecting a 35% difference in LDL receptor mRNA was 95% at each time point (4, 12, and 24 h), so that the lack of change in mRNA levels is meaningful when compared with changes of 56-72% in LDL receptor number. There was also no effect of QAYL on y-actin mRNA levels, and the ratio of LDL receptor mRNA to r-actin mRNA differed by less than 3% in control and QAYL-treated plates throughout the experiment (data not shown). However, Fig. 5B shows that QAYL increased synthesis of LDL receptor protein as assessed by incorporation of [35S]methionine/cysteine at 1 and 4 h by 87% (P = 0.006). LDL receptor protein stability was unaltered by QAYL as shown in the pulse-chase experiments of Fig. 5C . The half-life of LDL receptor protein was 8.2 f 0.6 h in control cells and 6.8 + 0.4 h in QAYL-treated cells (difference not significant).
To examine the generality of LDL receptor induction by growth factors, both fibroblasts and Hep G2 human liver cells were treated for 24 h with a single growth factor in BSA medium and then analyzed for LDL receptors (Table 1) . Under these conditions there was no increase in protein per well with any hormone treatment. Both fibroblasts and Hep G2 cells showed significant increases in LDL receptor activity per milligram of protein with IGF-II and transforming growth factor+31 (TGFPl), and fibroblasts responded as expected to platelet-derived growth factor-AA (PDGF-AA) treatment. Thus, several growth factors are capable of modifying LDL receptor expression to a similar degree in both fibroblast and liver cells.
DISCUSSION
There are few reports of the effects of IGF-I on cellular LDL metabolism in the literature, and two experimental difficulties seem to be partly responsible.
First, LDL receptors often are measured in the presence of LPDS to increase receptor expression to its maximum level. Under these conditions the further addition of IGF-I was without effect. However, a prominent increase in LDL (Fig. 1) or when physiological concentrations of LDL cholesterol were added back to the LPDS (Fig. 3) . The common thread in these experiments is that IGF-I increased LDL receptors in cells with reduced baseline receptor expression.
Second, although IGF-I increased LDL receptor activity consistently at doses as low as 2.5 rig/ml, attempts to analyze the binding data quantitatively by the Scatchard method gave inconsistent results (data not shown). This seems to due to the confounding effects of IGF-binding proteins known to be secreted by fibroblasts, which result in varying concentrations of free IGF-I over time in the culture medium (8, 9). When QAYL and BCM (IGF-I variants that bind to the IGF-I receptor but not to secreted IGF binding proteins) were used in place of IGF-I, the amount of hormone needed to stimulate LDL receptor activity was reduced more than 1 OO-fold ( Fig. 1 A) , and Scatchard plots of ['251]LDL binding were linear (Fig. 2B) . We conclude that fibroblast IGF-binding proteins are important experimental impediments to the study of IGF effects on LDL metabolism in cultured cells. Conversely, however, IGF-binding proteins may have an important regulatory role with respect to LDL receptors in the intact organism.
The principal action of IGF-I was to increase LDL receptor number. Figure 2 shows a 72% increase in maximum ['251 ]LDL binding capacity, and a similar 56% increase in total cell LDL receptor mass was observed in immunoblotting experiments. However, there was also a statistically significant 38% decrease in the dissociation constant for LDL, indicating an increase in affinity of the cells for LDL. The IGF-I receptor seems to mediate these effects, because increased LDL binding was blocked by a monoclonal antibody, a-IR3, which is specific to the IGF-I receptor (Fig. 4) .
Although there is a growing body of literature on the clinical effects of IGF-I on LDL metabolism (4, 10, 1 l), only specialized cells have been studied in tissue culture previously. It has been reported that IGF-I treatment of cultured swine granulosa cells increased LDL receptor number (12); however, because IGF-I stimulated a large increase in progesterone synthesis from cellular cholesterol, it is likely that in this case much of the effect on LDL receptors was due to cholesterol depletion. Recent work has established that murine monocyte-macrophages responded to both GH and IGF-I by increasing LDL degradation (13), consistent with increased LDL receptor activity or more rapid LDL processing. Our data show that the response to IGF-I is principally mediated by increased LDL receptor mass, and that it is not confined to specialized differentiated cells. The regulation of LDL receptor expression by cholesterol occurs at the level of transcription (14-16). Other hormones such as insulin (17, 18) and PDGF (19) also seem to augment transcription of LDL receptor mRNA. In contrast, LDL receptor mRNA measured with a sensitive solution hybridization assay was unchanged after IGF-I treatment, suggesting a posttranscriptional mechanism of control (Fig. 4) . Although not studied as exten- 
